Congenital adrenal hyperplasia (CAH) is a group of hereditary disorders that affect the adrenal glands. The adrenal glands produce the hormones cortisol and aldosterone. CAH is caused by genetic ...

Congenital adrenal hyperplasia is one of the most prevalent genetic endocrine diseases. A new guideline from the Endocrine Society offers expert opinion and evidence-based recommendations on the ...

Nonclassical congenital adrenal hyperplasia (NCAH) can lead to the production of excess male hormones. It is usually a mild condition and often doesn’t need to be treated. Nonclassical ...

A 29-year-old man was seen 2 years ago to transfer his care from pediatric to adult endocrinology. He was diagnosed at birth with classic congenital adrenal hyperplasia from 21-hydroxylase ...

The Commonest cause of Congenital Adrenal Hyperplasia is due to due to the mutations in the CYP21A2 gene leading to deficiency of 21-hydroxylase enzyme. This can lead to variations in cortisol and ...

Wilkins 12 stated that, up to 1946, of 83 cases of female pseudohermaphroditism due to congenital adrenal hyperplasia cortical insufficiency is known to have occurred in only 6, whereas of 16 ...

Congenital Adrenal Hyperplasia (CAH) can be diagnosed by several strategies. These include physical examination, measuring steroid hormone levels in blood / urine, x-rays of bones and genetic testing.

Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder where steroidogenesis in the adrenal cortex is impaired. The most common form is caused by 21-hydroxylase deficiency (21OHD).

Study shows crinecerfont aids patients with congenital adrenal hyperplasia. Crinecerfont results in a greater decrease from baseline in the mean daily glucocorticoid dose among patients with ...

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to ...

References: Neurocrine Biosciences announces FDA approval of Crenessity™ (crinecerfont), a first-in-class treatment for children and adults with classic congenital adrenal hyperplasia.

Orlando, Florida — New data add to the evidence supporting use of crinecerfont for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, in both adults and ...